Drugs / AD-231C
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07590167 | Jun → Jul 2026 overdue | hyperlipidemia, hypertensive disorder | Addpharma Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07312773 | Jan → Feb 2026 overdue | essential hypertension, hyperlipidemia | Addpharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-231C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07312773 ↗ |
| Route | Oral | “AD-231B+AD-231C Oral Tablet” NCT07312773 ↗ |